CA
NZ
UK
AU
IND
US
Cancer trial results matter for Actuate Therapeutics (NASDAQ:ACTU) because a single drug's performance against one of the deadliest cancers is essentially the whole company. Actuate is a clinical-stage biotechnology firm developing elraglusib, a drug that inhibits a protein called GSK-3-beta, as a treatment for …
Precision oncology could shape Acrivon Therapeutics (NASDAQ:ACRV) because matching the right cancer drug to the right patient is the company's core idea. Many cancer therapies work well in some patients and not others, and giving a drug to those unlikely to benefit exposes them …
Immunology research matters for Aclaris Therapeutics (NASDAQ:ACRS) because developing treatments for immune and inflammatory diseases is what the company does. Aclaris is a clinical-stage biotechnology firm working on therapies that modulate the immune system to treat conditions in which it malfunctions, inflammatory skin diseases …
Treatment adoption matters forAlphaCognition (NASDAQ:ACOG) because winning regulatory approval for a drug is only half the battle; the harder task is convincing physicians to prescribe it and payers to cover it. Alpha Cognition has moved past the approval milestone that stops most biotechs in …
Aclarion (NASDAQ:ACON) connects theNasdaqComposite to the search for a better way to diagnose chronic back pain, one of medicine's most common yet stubbornly imprecise conditions. Standard imaging, such as MRI, can show structural changes in the spine but often can't reliably identify which specific …
Brain-disease research matters for AC Immune (NASDAQ:ACIU) because treating neurodegenerative diseases is the company's entire purpose. AC Immune, a Swiss biotechnology company, develops therapies, including active immunotherapies that prompt the body's own immune system to attack disease-causing proteins, aimed at Alzheimer's, Parkinson's, and related …
Achieve Life Sciences (NASDAQ:ACHV) is trying to bring a new stop-smoking pill to market. A recent FDA rejection was about manufacturing, not the drug's effectiveness, so the company is fixing the problem and preparing to try again, with a vaping-cessation opportunity behind it.
Advanced Biomed (NASDAQ:ADVB) is developing tiny biochips to detect cancer cells in the blood, a form of so-called liquid biopsy. It is a very small, recently listed company, so its scientific promise is matched by considerable uncertainty, and investors evaluating the stock need to …
Addus HomeCare (NASDAQ:ADUS) helps elderly and disabled people stay in their own homes with personal care, home health and hospice services. SteadyDemandand disciplined acquisitions lifted revenue 8% in the second quarter, and profits grew faster still, a combination that reflects both a durable demographic …
ADMA Biologics (NASDAQ:ADMA) makes medicines from human plasma, and a specialty immune-boosting product for vulnerable patients has become the company's dominant growth engine. Rising sales of that high-margin product lifted profits again in the second quarter, even as an older, lower-margin product in the …
Please wait processing your request...